NCT06977594Recruiting
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
A Randomized, Placebo-controlled, Parallel-group, Open-label Trial to Evaluate the Efficacy of Proactive Immune Tolerance Induction to Paclitaxel and Carboplatin in Patients With Gynecologic Cancer
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer. The main questions it aims to answer are: \- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles? Participants will: * Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment. * Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 3 May 2025
- Start date
- 21 May 2025
- Primary completion date
- 31 May 2027
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Endometrial cancer, Cervical cancer, Ovarian cancer
- NCT number
- NCT06977594
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 21 May 2025 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who do not wish to participate in this study voluntarily.
- Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.
Who the study is looking for
- Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies.
- Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin.
- Patients who are able to read and voluntarily provide written informed consent.
- Aged 19 years or older.
Age in the registry: 19 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.